Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Torisel in refractory and recurrent primary CNS lymphoma
NCT00942747Phase 2Unknown
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jul 2009
- Primary completion
- Dec 2013
- Countries
- 1
01
Overview
Phase 2, open-label trial of temsirolimus in primary central nervous system lymphoma (PCNSL), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Overall Response Rate at 48 weeks. Status: unknown.
02
Drugs
temsirolimus
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT00942747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00942747.